Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) — Capital Reinvestment Ratio
Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥502.01 Million) in capital expenditures (CN¥18.35 Million). Check Nanjing King-friend Biochemical Pharmace tangible equity quality to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Nanjing King-friend Biochemical Pharmaceutical Co Ltd Capital Reinvestment Ratio (2013–2025)
This chart tracks Nanjing King-friend Biochemical Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 9 annual periods. For the full cash flow conversion analysis, see 603707 cash flow conversion.
Annual Capital Reinvestment Ratio for Nanjing King-friend Biochemical Pharmaceutical Co Ltd (2013–2025)
Year-by-year Capital Reinvestment Ratio for Nanjing King-friend Biochemical Pharmaceutical Co Ltd from 2013 to 2025. See 603707 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.47x | CN¥1.18 Billion | CN¥560.15 Million | ▲ +40.3% |
| 2024 | 0.34x | CN¥1.50 Billion | CN¥506.82 Million | ▲ +30.4% |
| 2023 | 0.26x | CN¥1.62 Billion | CN¥419.07 Million | ▼ -67.2% |
| 2022 | 0.79x | CN¥595.45 Million | CN¥470.08 Million | ▲ +22.4% |
| 2021 | 0.64x | CN¥683.63 Million | CN¥440.76 Million | ▼ -51.4% |
| 2018 | 1.33x | CN¥62.37 Million | CN¥82.76 Million | ▲ +632.5% |
| 2015 | 0.18x | CN¥137.28 Million | CN¥24.87 Million | ▲ +10.2% |
| 2014 | 0.16x | CN¥178.74 Million | CN¥29.40 Million | ▼ -48.5% |
| 2013 | 0.32x | CN¥193.91 Million | CN¥61.96 Million | — |